Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study

SC Burnham; PM Coloma; QX Li; S Collins; G Savage; S Laws; J Doecke; P Maruff; RN Martins; D Ames; CC Rowe; CL Masters; VL Villemagne

Journal article

Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study

SC Burnham, PM Coloma, QX Li, S Collins, G Savage, S Laws, J Doecke, P Maruff, RN Martins, D Ames, CC Rowe, CL Masters, VL Villemagne

Journal of Prevention of Alzheimer S Disease | EDITIONS SERDI | Published : 2019

DOI: 10.14283/jpad.2019.25

Abstract

BACKGROUND: The National Institute on Aging and Alzheimer's Association (NIA-AA) have proposed a new Research Framework: Towards a biological definition of Alzheimer's disease, which uses a three-biomarker construct: Aß-amyloid, tau and neurodegeneration AT(N), to generate a biomarker based definition of Alzheimer's disease. OBJECTIVES: To stratify AIBL participants using the new NIA-AA Research Framework using cerebrospinal fluid (CSF) biomarkers. To evaluate the clinical and cognitive profiles of the different groups resultant from the AT(N) stratification. To compare the findings to those that result from stratification using two-biomarker construct criteria (AT and/or A(N)). DESIGN: Indi..

View full abstract

University of Melbourne Researchers

Qiao-Xin Li Author

Steven Collins Author

Paul Maruff Author

David Ames Author

Grants

Funding Acknowledgements

Core funding for the AIBL study was provided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF) in partnership with the CRC for Mental Health, Edith Cowan University (ECU), Mental Health Research Institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, Macquarie University, CogState Ltd, Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The study also received funding from the National Health and Medical Research Council (NHMRC), Dementia Collaborative Research Centre (DCRC) program, and McCusker Alzheimer's Research Foundation, and operational infrastructure support from the Government of Victoria. This specific study was funded in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland. The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; in the preparation of the manuscript; or in the review or approval of the manuscript.